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ABSTRACT 
Labetalol Hydrochloride is a β-blocker generally indicated for the treatment of hypertension, and it is extensively metabolized due to the 
hepatic metabolism. In the present work, an attempt was made to mask the taste by Solid Dispersion technique, with a formulation into Fast 
Disintegrating dosage form, using superdisintegrants such as Cross carmellose sodium (CCS), crospovidone (CP) and sodium starch glycolate 
(SSG). The complexes of Labetalol hydrochloride with HP-β-CD (1:3 ratio) were prepared by Co-precipitation method. Using the drug HP-β-CD 
complex, Fast Disintegrating tablets were prepared by Wet granulation Technique and evaluated for hardness, friability, weight variation, 
thickness, disintegrating time (DT), In-vitro dispersion time and  dissolution rate. The results of Direct compression optimized formulation 
WG9 (Sodium Starch Glycolate 15mg and Starch paste 18mg) has shown the % Drug release of  99.97%, In-vitro Dispersion time of 16 Secs 
respectively.  
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INTRODUCTION: 
Oral route has been one of the most popular routes of drug 
delivery due to its ease of administration, patient 
compliance, least sterility constraints and flexible design of 
dosage forms. For many decades treatment of an acute 
disease or chronic illness has mostly accomplished by 
delivery of drugs to patients using conventional drug 
delivery system. Even today these conventional drug 
delivery systems are the primary pharmaceutical products 
commonly seen in the prescription.  Conventional oral drug 
products are formulated to release the active principle 
immediately after oral administration to obtain rapid and 
complete systemic drug absorption.1 
Difficulty in swallowing (dysphagia) is common among all 
age groups, especially in elderly, and is also seen in 
swallowing conventional tablets and capsules. The novel 
technology of fast-disintegrating dosage forms is known as 
fast dissolve, rapid dissolve, rapid melt and quick 
disintegrating tablets. A solid dosage form that dissolves or 
disintegrates quickly in the oral cavity, resulting in solution 
or suspension without the need for the administration of 
water, is known as an fast-disintegrating dosage form.2 
 Taste is one of the most important parameters governing 
patient compliance. Undesirable taste is one of several 
important formulation problems that are encountered with 
certain drugs. Taste masking is defined as a perceived 
reduction of an undesirable taste that would otherwise 
exist.3-6 
Labetalol HCl is a blocker of both alpha- and beta-adrenergic 
receptors that is used as an antihypertensive agent. 
Labetalol is used parenterally for immediate reduction in 
blood pressure in severe hypertension or in hypertensive 
crises when considered an emergency, for the control of 
blood pressure in patients with pheochromocytoma and 
pregnant women with preeclampsia, and to produce 
controlled hypotension during anesthesia to reduce bleeding 
resulting from surgical procedures. Absorption Completely 
absorbed (100%) from the gastrointestinal tract with peak 
plasma levels occurring 1 to 2 hours after oral 
administration. The absolute bioavailability of labetalol HCl 
is increased when administered with food.7-8  
MATERIALS AND METHODS: 
Labetalol HCl supplied by Pharma Train, HP-Betacyclo 
dextrin Purchased from Signet Chemicals Co. Ltd., (Mumbai, 
India), Crosspovidone was and Crosscarmellose sodium, was 
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purchased from Yaroow chemicals and pharmaceuticals ( 
Mumbai , India) Sodium Starch Glycolate and MCC was 
obtained as a gift sample from Maple Biotech India pvt,Ltd 
(Pune , India), Talc , Mannitol, Magnesium Stearate 
Purchased from S.D. Fine Chem. Ltd. 
Drug polymer compatibility studies: 
1. Fourier Transform Infrared Spectroscopy (FTIR): 
Ten milligrams of drug alone, mixture of drug and polymer 
were weighed and mixed properly with KBr uniformly. A 
small quantity of the powder was compressed into a thin 
semitransparent pellet by applying pressure. The IR-
spectrum of the pellet from 450- 4500cm-1. (Figure no. 1,2) 
2. Differential Scanning Calorimetric (DSC): 
Differential scanning calorimeter (DSC) was performed 
using Perkin Elmer instruments, 
(Perkin Elmer DSC-7, Norway, USA.) to study the thermal 
behaviour of labetalol hydrochloride and mixture of drug 
and polymers. (Figure no. 3,4)  
Preparation of Solid Dispersion by Co – Precipitation 
Method: 
Drug was dissolved in ethanol at room temperature and 
polymer was dissolved in distilled water. Different molar 
ratios of Drug and polymer (1:1, 1:2 and 1:3) were taken. 
The mixture was stirred at room temperature, for one hour 
and then slowly evaporated on a boiling water bath. The 
inclusion complex precipitated as a crystalline powder was 
pulverized and passed through sieve No. 80 and stored in a 
desiccator till free from any traces of the organic solvent.
  
Table no.1: Formulation codes for the Labetalol HCl solid dispersions 
Ingredients (mg) 
Formulation code 
SD1 SD2 SD3 SD4 SD5 SD6 
Labetalol HCl 100 100 100 100 100 100 
Beta cyclodextrine 100 200 300 - - - 
HP-Beta cyclodextrine - - - 100 200 300 
 
In both the Polymer’s used HP-Betacyclodextrine > 
Betacyclodextrine  
Drug: Polymer complex of SD6 (Drug: HP-Betacyclo dextrin 
1:3 & by Co-precipitate method) is having the better 
solubility enhancement. (Table no. 3, Figure no. 5) 
Preparation of Labetalol HCl of fast disintegrating 
tablets by Wet granulation technique 
All the powders were passed through #80 mesh sieve. 
Required quantity of drug mixture (Solid dispersion) and 
excipients were mixed thoroughly. Mixture was then 
granulated using Starch paste and granules were made. 
Granules were dried at 40˚C for about 15 min. After drying 
super disintegrants was added externally. Talc and 
magnesium stearate were added as glident and lubricant 
respectively. The tablet was compressed using 9mm round 
flat punches to get tablets of 300mg weight on 10 station 
rotary tablet machine (CLIT). 
 
Table no. 2. Formulation Design of Labetalol HCl using Wet Granulation Technique 
Ingredients (mg) WG0 WG1 WG2 WG3 WG4 WG5 WG6 WG7 WG8 WG9 
Labetalol+HP Betacyclodextrine 
(SD6) 
200 200 200 200 200 200 200 200 200 200 
Crospovidone - 5 10 15       
Cross carmellose sodium -    5 10 15    
Sodium starch glycolate -       5 10 15 
Starch paste 8 12 12 12 15 15 15 18 18 18 
Mannitol 84 75 70 65 72 67 62 69 64 59 
Talc 3 3 3 3 3 3 3 3 3 3 
Magnesium stearate 3 3 3 3 3 3 3 3 3 3 
Pippermint flavor 2 2 2 2 2 2 2 2 2 2 
Total weight 300 300 300 300 300 300 300 300 300 300 
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Pre Compression Parameters 
Angle of Repose 
Angle of repose was determined using cylinder method. The 
blend was poured through a funnel that can be raised 
vertically until a maximum cone height (h) was obtained. 
Radius of the heap (r) was measured and the angle of repose 
(q) was calculated using the formula (Table no.4) 
                       Ɵ = tan-¹(r/ h) 
Bulk density: 
Bulk density of powdered blend was determined by pouring 
gently through a glass funnel into 50 ml graduate9d cylinder. 
The volumes occupied by the samples were recorded. Bulk 
density was calculated as: 
              
                         
                             
 
Tapped density: 
An accurately weighed sample of powder was carefully 
added to the cylinder with the aid of a funnel. Typically, the 
initial volume was noted, and the sample is then tapped 
(500, 750 or 1250 tapping) until no further reduction in 
volume is noted or the percentage of difference is not more 
than 2%. A sufficient number of taps should be employed to 
assure reproducibility for the material in question. Volume 
was noted and taped density is calculated using following 
formula.10 
                
                    
             
 
Compressibility Index : 
One of the important measures that can be obtained from 
bulk and tapped density determinations is the percent 
Compressibility or the Carr`s Index,I which is determined by 
the following equation.11 
  I = Tapped density –Bulk Density/ Tapped density 
Hausner`s Ratio:  
Hausner`s Ratio is defined as a ratio of a tapped density to 
bulk density. It is a measure of relative importance of 
interparticulate interactions. A Hausner ratio greater than 
1.25 is considered to be an indication of poor flowability.11 
                      Hausners Ratio= Tapped Density/ Bulk denisty 
Evaluation of Post-Compression Parameters: 
a. Weight variation test:12 
Twenty tablets were selected randomly from each 
formulation, weighed individually and the average weight 
and % variation of weight was calculated. (Table no. 5) 
b. Thickness:13 
Six tablets of each batch were selected and measured for 
thickness and diameter using the digital venire calipers. The 
extent to which the thickness of each tablet deviated from 
±5% of the standard value was determined. 
c. Hardness: 
Hardness was measured using the Monsanto hardness 
tester. Measure the pressure required to break 
diametrically placed matrix tablet, by a coiled spring. 
d. Friability test: 
The friability of the tablets was determined by using the 
Roche Friabilator. It is expressed in percentage (%). Ten 
tablets were initially weighed (Winitial) and transferred into 
the friabilator. The friabilator was operated at 25 rpm for 
four minutes. The tablets were weighed again (Wfinal). The 
percentage friability was then calculated using the equation 
                                         F= (Winitial – Wfinal x 100) / Winitial% 
Friability of tablets less than 1% was considered acceptable. 
The friability was expressed as the loss of mass and was 
calculated as a percentage of the initial mass. 
e. Drug Content: 
10 Tablets were taken and powdered. Powder equivalent to 
one tablet was weighed accurately and allowed to dissolve 
in 10ml phosphate buffer and makeup the volume up to 
100ml. The solution was filtered; 1ml of filtrate was taken 
in 50ml of volumetric flask and diluted up to the mark with 
6.8 phosphate buffer and analyzed spectrophotometrically 
at 305nm.14 
f. Wetting time and water absorption ratio: 
A piece of tissue paper folded twice was placed in a small 
Petri dish containing 6ml of water. A tablet was carefully 
placed on the surface of the tissue paper. The time required 
for water to reach the upper surface of the table was noted 
as the wetting time. 
Water absorption ratio (R) was calculated using the formula: 
R=100 x [Wa – Wb] / Wb, 
where, Wa=weight of tablet after absorption, Wb=weight of 
tablet before absorption. 
g. In-vitro disintegration time: 
The disintegration time for all formulations was carried out 
using a tablet disintegration test apparatus. Six tablets were 
placed individually in each tube of the disintegration test 
apparatus and the disks were placed. The water was 
maintained at a temperature of 37±2°C and the time taken 
for the entire tablet to disintegrate completely was noted. 
h. In-vitro dispersion time: In-vitro dispersion time was 
measured by dropping a tablet in a measuring cylinder 
containing 6 ml of simulated saliva fluid (pH 6.8). Three 
tablets from each formulation were randomly selected 
and in-vitro dispersion time was expressed in seconds. 
i. In-vitro drug release studies: 
In-vitro drug release studies were carried out using the USP 
XXIII Dissolution Apparatus II (Paddle Type) at 50 rpm. The 
drug release profile was studied in 900 ml of phosphate 
buffer pH-6.8 as dissolution medium. Temperature was 
maintained at 37±0.5°C. Aliquots of 5 ml of dissolution 
medium were withdrawn at specific time intervals at every 
five minutes and filtered. The amount of drug released was 
determined by the UV-Visible spectrophotometer at 305nm 
and concentration of drug was determined from standard 
calibration curve.16 (Table no. 6 Fig no. 6)  
g. Stability studies: 
Stability studies were performed at a temperature of 25±20C 
/ 65±5%RH & 4020C/755%RH, over a period of three 
months (90 days) on the promising FDT of Labetalol HCl 
formulation (Table no. 8) 
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RESULTS AND DISCUSSION: 
FT-IR Spectroscopic Analysis: 
 
Fig 1 FTIR graph for Labetalol HCl (Pure Drug) 
 
Fig: 2 FTIR graph for Labetalol HCl + Excipients 
Differential Scanning Calorimetry (DSC) Studies 
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Fig :3 DSC of Pure Drug 
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Fig:4 DSC of Optimized Formulation (WG9) 
DSC thermogram of untreated/ pure drug shows an 
endothermic peak at 158℃ , which is related to its melting 
point. Physical mixture of excipients and the drug of the 
Optimized Formulation WG9 showed endothermic peaks at 
174.51℃ . It was found that there are no new peaks 
appeared in the thermogram of the drug and excipients. 
Thus, there is no interaction between the drug and the tablet 
excipients, was observed. However, there is a very slight 
shift in the drug peak and this might be due to a reduction of 
the purity of components by mixing. 
 
Table :3 Dissolution data of Labetalol Solid dispersions 
Time(min) SD1 SD2 SD3 SD4 SD5 SD6 
0 0 0 0 0 0 0 
5 8.91±0.052 15.02±0.054 12.76±0.068 9.28±0.01 15.43±0.012 26.65±0.025 
10 11.55±0.020 18.85±0.056 18.28±0.011 12.26±0.065 20.68±0.0.019 35.05±0.043 
15 15.56±0.078 21.9±0.067 24.36±0.025 16.15±0.087 26.97±0.053 46.15±0.044 
20 19.34±0.049 28.22±0.078 31.16±0.045 20.86±0.054 32.87±0.045 56.35±0.062 
30 23.19±0.067 34.8±0.023 37.88±0.034 24.31±0.054 39.45±0.054 67.6±0.068 
40 27.75±0.087 42.92±0.034 44.49±0.053 28.4±0.053 47.58±0.052 82.6±0.079 
50 29.47±0.067 45.3±0.051 48.44±0.791 30.46±0.078 50.76±0.088 86.9±0.062 
60 31.26±0.003 46.87±0.33 51.28±0.34 32.09±0.04 54.38±0.02 93.12±0.022 
 
 
Fig 5: Comparative dissolution profile for labetalol HCl Solid Dispersion 
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Table 4: Pre compression studies of Labetalol HCl fast disintegrating tablets (Wet Granulation Technique) 
Formulation 
Code 
Bulk density 
Tapped 
density 
Cars index 
Hausners 
ratio 
Angle of 
repose (     
WG0 0.26±0.07 0.30±0.06 13.84±0.04 1.16±0.04 33.72±0.03 
WG1 0.28±0.09 0.32±0.09 12.95±0.13 1.15±0.11 32.62±0.15 
WG2 0.29±0.12 0.31±0.11 8.29±0.`5 1.09±0.12 29.47±0.18 
WG3 0.29±0.14 0.31±0.12 4.90±0.16 1.05±0.15 25.58±0.14 
WG4 0.32±0.15 0.34±0.13 5.66±0.18 1.06±0.16 26.77±0.17 
WG5 0.31±0.17 0.34±0.14 7.99±0.14 1.09±0.20 28.47±0.19 
WG6 0.32±0.18 0.35±0.17 7.79±0.12 1.08±0.19 27.17±0.23 
WG7 0.30±0.16 0.32±0.18 8.83±0.16 1.10±0.16 29.58±0.22 
WG8 0.29±0.15 0.32±0.16 9.70±0.17 1.11±0.14 30.11±0.15 
WG9 0.28±0.08 0.32±0.09 10.52±0.10 1.12±0.18 31.42±0.11 
 
 Table: 5 Post compression studies of Labetalol HCl fast disintegrating tablets (Wet Granulation Technique) 
Formulation 
Code 
% weight 
variation 
Thickness 
(mm) 
Hardness 
(Kg/cm2) 
% 
friability 
Disintegration 
time (Sec) 
In-vitro 
Dispersion 
time (Sec) 
Water 
absorption 
ratio 
% Drug 
Content  
WG0 293.2 3.59±0.10 2.5±0.20 0.45±0.05 62.54±0.11 58.39±0.10 62.48±0.23 101.42±0.18 
WG1 300.5 4.17±0.17 3.2±0.05 0.38±0.15 56.49±0.16 49.58±0.14 73.58±0.31 99.86±0.15 
WG2 301.4 4.12±0.25 3.4±0.11 0.28±0.11 42.47±0.21 35.39±0.17 79.68±0.29 99.35±0.23 
WG3 298.9 4.08±0.10 3.5±0.15 0.51±0.15 39.59±0.29 34.96±0.20 76.4±0.19 100.83±0.31 
WG4 299.1 4.18±0.17 3.3±0.15 0.37±0.13 41.59±0.28 40.87±0.19 89.57±016 100.43±0.49 
WG5 301.3 4.1±0.10 3.5±0.25 0.54±0.07 25.39±0.31 21.98±0.16 91.47±0.14 101.16±0.66 
WG6 299.4 4.16±0.11 3.5±0.10 0.28±0.09 30.59±0.42 24.51±0.29 92.48±0.16 100.34±0.52 
WG7 298.1 4.12±0.05 3.5±0.10 0.36±0.06 28.49±0.17 21.43±0.25 87.48±0.15 99.38±0.41 
WG8 302.4 4.19±0.10 3.1±0.10 0.34±0.10 29.51±0.22 19.39±0.20 88.39±0.22 99.51±0.53 
WG9 299.5 4.07±0.05 3.5±0.10 0.36±0.11 22.94±0.19 16.49±0.18 85.39±0.10 99.61±0.33 
 
 Table :6 Dissolution data of various fast disintegrating tablets of Labetalol HCl (Wet Granulation Technique) 
Time 
(min) 
WG0 WG1 WG2 WG3 WG4 WG5 WG6 WG7 WG8 WG9 
0 0 0 0 0 0 0 0 0 0 0 
5 
2.98±0.1
2 
30.29±0.
15 
32.94±0.
20 
32.19±0.
12 
31.84±0.
29 
42.98±0.
21 
43.29±0.
29 
35.38±0.
30 
39.29±0.
21 
43.19±0.
24 
10 
6.75±0.0
9 
47.28±0.
19 
54.27±0.
22 
63.86±0.
19 
63.29±0.
32 
76.37±0.
29 
73.49±0.
27 
54.12±0.
29 
71.39±0.
29 
75.47±0.
29 
15 
8.19±0.1
2 
71.39±0.
20 
77.47±0.
19 
87.97±0.
21 
87.46±0.
30 
99.71±0.
19 
93.74±0.
20 
74.25±0.
21 
92.38±0.
20 
99.97±0.
16 
20 
10.92±0.
15 
88.27±0.
22 
92.46±0.
18 
99.46±0.
18 
98.46±0.
16 
99.70±0.
16 
99.96±0.
19 
91.38±0.
19 
99.51±0.
17 
99.96±0.
16 
25 
13.05±0.
08 
99.31±0.
30 
99.21±0.
21 
99.45±0.
18 
99.93±0.
11 
99.69±0.
17 
99.95±0.
18 
99.73±0.
15 
99.50±0.
16 
99.95±0.
16 
30 
16.95±0.
17 
99.30±0.
34 
99.19±0.
21 
99.44±0.
18 
99.92±0.
11 
99.70±0.
16 
99.94±0.
19 
99.72±0.
15 
99.48±0.
17 
99.97±0.
16 
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Fig: 6 Comparative dissolution profile 
 
Table :7 Comparative dissolution profile for Marketed 
formulation (Trandate) and WG9 
Time(min) Marketed formulation WG9  
0 0 0  
5 23.21±0.21 43.19±0.20  
10 42.83±0.19 75.47±0.16  
15 64.53±0.26 99.92±0.18  
20 79.32±0.22 99.96±0.19  
25 91.43±0.19 99.95±19  
30 99.65±0.18 99.93±17  
 
 
Fig:7 Comparative dissolution profile for WG9 and 
Marketed forrmulation 
 
Stability studies: There is no change in drug content and 
% drug release for the period of 3 months, so it is 
continued for the next three months as per ICH guidelines 
for stability studies. 
 
Table :8 Stability studies for optimized formulation WG9 
Formulation 
Code 
In-vitro 
Dispersion 
time (Sec) 
% Drug 
Content 
% Drug released 
25±20C / 
65±5%RH 
40±20C / 
75±5%RH 
Fisrt day 16.49±0.14 99.61±0.11 99.61±0.19 99.61±0.20 
30 days 16.51±0.11 99.41±0.23 99.53±0.16 99.59±0.18 
60 days 16.33±0.15 99.24±0.19 99.42±0.27 99.52±0.29 
90 days 16.22±0.14 99.06±0.27 99.32±0.30 99.45±0.22 
 
CONCLUSION 
For this study Fast disintegrating tablet are prepared by 
using Labetalol HCl as a model drug is used as Anti- 
Hypertensive. From the Solid Dispersion studies it can be 
concluded that In vitro dissolution studies for solid 
dispersion has been performed and the results shows that 
SD6  shows the greater drug release than compared to the 
other dispersions. SD6 containing 1: 3 concentration of Drug 
and HP Beta cyclodextrin shows the best suitable Solid 
dispersion to be used for taste masking and to enhace the 
ensolubility of the drug. 
Labetalol HCl Fast Disintegrating Tablets was successfully 
prepared by using Direct compression Technique. 
Evaluation parameters like Weight variation, Thickness, 
Hardness, Friability, and drug content indicate that values 
were within permissible limit for all formulations. In vitro 
drug release study was carried out Fast disintegrating 
tablets prepared by Wet Granulation technique and based on 
the results; WG9(Containing 15mg of Sodium Starch 
Glycolate) showed the % Drug release of  99.97%, In-vitro 
Dispersion time of 16 Secs respectively was identified as the 
best formulation among all the other formulations.  The 
Sodium Starch Glycolate used formulation has shown better 
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release profile than compared with other formulations by 
Direct Compression Technique. The optimized formulation 
follows first order kinetics with regression coefficient WG9 
0.998 respectively. Stability studies indicate that the 
formulated oral disintegrating tablets are stable for a period 
of 3 months under two different conditions. 
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